Asterias Biotherapeutics Announces New Exclusive License Agreement with The Regents of the University of California for Strok...
12 Luglio 2018 - 1:00PM
Asterias Biotherapeutics, Inc. (NYSE American:AST), a biotechnology
company dedicated to developing cell-based therapeutics to treat
neurological conditions associated with demyelination and cellular
immunotherapies to treat cancer, today announced that it has
entered into an exclusive license agreement with The Regents of the
University of California. Under the agreement, the Company
has exclusive rights in all fields of use for a patent family that
claims a method of improving recovery in a patient that has
suffered an ischemic stroke by administering to the patient stem
cell-derived oligodendrocyte progenitor cells. The pending
patent applications in the US, Canada, China, Japan, Australia, and
before the European Patent Organization that are included in the
exclusive license were filed after initial testing of AST-OPC1, the
Company’s pluripotent stem cell derived oligodendrocyte progenitor
cell product, in a rodent model of white matter ischemia in
collaboration with Dr. S. Thomas Carmichael, M.D., Ph.D., Chair and
Professor of Neurology at the University of California, Los Angeles
(“UCLA”). The pending patents are jointly owned by The
Regents of The University of California and Asterias, with The
Regents granting the Company an exclusive license to its share of
the IP rights.
The exclusive license agreement with the Regents
of the University of California is a part of the Company’s strategy
to explore the efficacy of its AST-OPC1 product candidate in other
neurological conditions. AST-OPC1 is currently in a Phase
1/2a clinical trial in severe spinal cord injury (NCT02302157).
“The preliminary results of our ongoing spinal
cord injury trial are encouraging and we are excited to begin to
expand our neurology platform to other indications,” commented
Michael Mulroy, President and Chief Executive Officer. “We
look forward to exploring whether our AST-OPC1 product candidate
can help patients that have suffered an ischemic stroke and other
patients with demyelinating conditions where there is a large,
unmet medical need.”
The Company also announced that it has initiated
testing of AST-OPC1 in a second pre-clinical model of subcortical
and white matter ischemia in collaboration with a leading expert in
pre-clinical models of cerebral ischemia and cell transplantation.
About Asterias
Biotherapeutics
Asterias Biotherapeutics, Inc. is a
biotechnology company dedicated to developing cell-based
therapeutics to treat neurological conditions associated with
demyelination and cellular immunotherapies to treat cancer.
Asterias is presently focused on advancing three clinical-stage
programs which have the potential to address areas of very high
unmet medical need in the fields of neurology and oncology.
AST-OPC1 (oligodendrocyte progenitor cells) is currently in a Phase
1/2a dose escalation clinical trial in spinal cord injury. AST-VAC2
(antigen-presenting allogeneic dendritic cells) is an allogeneic
cancer immunotherapy. The company's research partner, Cancer
Research UK, has commenced a first-in-human clinical trial of
AST-VAC2 in non-small cell lung cancer. AST-VAC1
(antigen-presenting autologous dendritic cells) is an autologous
cancer immunotherapy with promising efficacy and safety data from a
Phase 2 study in Acute Myeloid Leukemia (AML). Additional
information about Asterias can be found at
www.asteriasbiotherapeutics.com.
FORWARD-LOOKING STATEMENTS
Statements pertaining to future financial and/or
operating and/or clinical research results, future growth in
research, technology, clinical development, and potential
opportunities for Asterias, along with other statements about the
future expectations, beliefs, goals, plans, or prospects expressed
by management constitute forward-looking statements. Any statements
that are not historical fact (including, but not limited to
statements that contain words such as "will," "believes," "plans,"
"anticipates," "expects," "estimates," “explores”) should also be
considered to be forward-looking statements. Forward-looking
statements involve risks and uncertainties, including, without
limitation, risks inherent in the development and/or
commercialization of potential products, uncertainty in the results
of clinical trials or regulatory approvals, need and ability to
obtain future capital, and maintenance of intellectual property
rights. Actual results may differ materially from the results
anticipated in these forward-looking statements and as such should
be evaluated together with the many uncertainties that affect the
businesses of Asterias, particularly those mentioned in the
cautionary statements found in Asterias' filings with the
Securities and Exchange Commission. Asterias disclaims any intent
or obligation to update these forward-looking statements.
Contacts:Investor
Relations(510) 456-3892InvestorRelations@asteriasbio.com orEVC
Group LLCMichael Polyviou/Todd Kehrli(732)
933-2754mpolyviou@evcgroup.com/tkehrli@evcgroup.com
Grafico Azioni Asterias Biotherapeutics, Inc. (AMEX:AST)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Asterias Biotherapeutics, Inc. (AMEX:AST)
Storico
Da Giu 2023 a Giu 2024